In light of this, the current paper aims to offer a thorough analysis of the effectiveness of afatinib in the therapy of NSCLC patients with various uncommon EGFR mutations, which can help medical professionals decide what the most effective strategy for individuals with such mutations is. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.